|
PRODUCT
DESCRIPTION
Innurex is a novel gene-based therapeutic for nerve repair. Oxford BioMedica’s LentiVector® technology is the most versatile system currently available for
delivering genes to cells of the central and peripheral nervous
system. Innurex is a product that uses this technology to deliver
a gene that induces neurons to produce neurite outgrowths. This
strategy opens the possibility of creating new nerve connections
to repair spinal injury.
INDICATION
Spinal
cord and avulsion injuries.
MARKET
Market estimates for Europe and the USA range from US$0.5-2.0 billion.
TECHNICAL
DESIGN
LentiVector
delivering the human RARß2 gene, a proprietary nuclear retinoic
acid receptor gene, to induce neurite outgrowth in damaged nerves.
DEVELOPMENT
STATUS
- Preclinical studies in models of spinal cord injury
have demonstrated that Innurex provides a statistically significant
improvement in both sensory and motor functional ability
compared to placebo for most measurements. The results were published
in Nature Neuroscience in February 2006
- These data add to previous
encouraging observations in preclinical models of avulsion
(stretch) injury and suggest that Innurex
may be useful in the clinical treatment of both stretch injury and
the technically more challenging spinal cord damage
- Further
preclinical studies are being conducted and a clinical plan
for initial trials of Innurex is being defined
COMMERCIALISATION
STRATEGY
Commercial partners sought to co-develop and
market the product.
PARTNERS/FUNDING
King's College
London, UK
The Christopher Reeve Paralysis Foundation (grant awarded to collaborator
King's College London)
Website by College Hill - Life Sciences |
